CRISPR Therapeutics AG's Chief Executive Officer just picked up 13,800 shares

Samarth Kulkarni, CRISPR Therapeutics AG's Chief Executive Officer and a director of the company, recently acquired 13,800 shares of the company. The buys took place at $1.81 per share, on December 29, 2020. Kulkarni now owns 182,989 shares of the company. Kulkarni operates out of Cambridge, MA. Some additional info was provided as follows:


This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter.

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever CRISPR Therapeutics AG makes a similar move, sign up!

Other recent filings from the company include the following:

CRISPR Therapeutics AG's Chief Executive Officer just cashed-in 30,000 options - June 17, 2021
CRISPR Therapeutics AG director just disposed of 10,000 shares - June 15, 2021
CRISPR Therapeutics AG director was just granted 10,000 options - June 14, 2021
Amendments to Articles of Incorporation or - June 14, 2021
Statement of changes in beneficial ownership of securities - June 14, 2021

Auto Refresh

Feedback